You are using an outdated browser. Please upgrade your browser to improve your experience.

You are using an outdated browser.

To ensure optimal security, this website will soon be unavailable on this browser. Please upgrade your browser to allow continued use of ACP websites.

Rheumatoid Arthritis: Tuberculosis Screening

Percentage of patients 18 years and older with a diagnosis of rheumatoid arthritis who have documentation of a tuberculosis (TB) screening performed within 12 months prior to receiving a first course of therapy using a biologic disease-modifying anti-rheumatic drug (DMARD).

Date Reviewed: April 27, 2015

Measure Info

MIPS 176NQF 2522CMS 176Approved for Trial Use
Measure Type: 
Process
Measure Steward: 
American College of Rheumatology
Clinical Topic Area: 
Rheumatoid Arthritis

Care Setting: 
Outpatient
Data Source: 
Registry

ACP supports NQF 2522 for physicians managing Rheumatoid Arthritis (RA): “Rheumatoid Arthritis: Tuberculosis Screening.” Biologic Disease-Modifying Anti-Rheumatic (DMARD) therapy can reactivate latent tuberculosis, leading to significant morbidity and even mortality. Administrative data suggests that over 1 in 4 individuals with RA receive biologic DMARDs. Over 1.3 million individuals in the United States have RA; therefore this measure is expected to impact over 300,000 Americans with RA. This is a physician level measure and should only be applicable to physicians who are managing and providing medical therapy for RA. Most often this will apply to rheumatologists, but primary care physicians may also manage RA.

As part of an ongoing effort to improve user experience, we have made some updates to the Performance Measures section of ACP. Tell us what you think!